Watertown biotech Selecta touts improved gout drug data in trial

Results from a trial of Selecta Biosciences' gout treatment show that it may be more effective than an already-approved drug that generated $157 million in sales last year, the company said Friday. Watertown-based Selecta (Nasdaq: SELB) is developing a biologic called SEL-212 to treat for chronic, severe gout, a form of arthritis caused by too much uric acid in the body. It’s the farthest along in the trial process of the biotech’s two drugs now in human studies, and the company is aimin g to…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news